Valeant Pharmaceuticals’ affiliate has entered into a collaboration agreement with AstraZeneca under which Valeant was granted an exclusive license to develop and commercialize brodalumab, an IL-17 receptor monoclonal antibody in development for moderate-to-severe plaque psoriasis and psoriatic arthritis. Valeant has exclusive rights to develop and commercialize brodalumab globally, except in Japan and certain other Asian countries, and is responsible for all development costs associated with...